Gland Pharma Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Efficient capital deployment (ROCE 15.1%)
- ✓Attractively valued vs sector (P/E 38.7x vs industry 54.4x)
- ✓Virtually debt-free
Concerns
- ✗Trading near 52-week high (₹2,574)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
GLAND · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% |
| FII | 4.05% | 3.59% | 6.88% | 4.48% | 5.04% | 6.90% |
| DII | 24.17% | 25.23% | 32.83% | 35.37% | 34.80% | 33.27% |
| Public | 13.93% | 13.32% | 8.46% | 8.33% | 8.33% | 8.00% |
Corporate Events
Dividend - Rs 20 Per Sh
Dividend - Rs 18 Per Share
Annual General Meeting/Dividend - Rs 20 Per Share
Latest News
All news →Gland Pharma publishes mandatory newspaper notice
*Gland Pharma publishes mandatory newspaper notice.* This is a routine regulatory disclosure required under corporate norms. **No financial or operational impact** is expected from this filing. It does not indicate any change in business prospects or strategy. 📊 *STOCKS:* GLAND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
5 stocks added to MSCI India Standard Index
*5 stocks added to MSCI India Standard Index*. MSCI’s February index review added Dixon, JK Cement, Precision Camshafts, Gland Pharma, and Rossari Biotech. Inclusion may attract passive foreign inflows into these stocks. Index rebalancing impacts global fund tracking MSCI benchmarks. 📊 *STOCKS:* DIXON, JKCEMENT, PRECAM, GLAND, ROSSARI | 🏢 *SECTOR:* Indices | #MEDIUMIMPACT #MSCI
Gland Pharma gets USFDA nod for glaucoma drug
*Gland Pharma gets USFDA nod for glaucoma drug.* The approval boosts its product portfolio and export potential. Shares rose on NSE following the news. The drug’s launch could contribute **revenue of ₹100–150 crore** annually in the medium term. 📊 *STOCKS:* GLAND | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDAApproval
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.7K Cr ▲2.8% | ₹1.7K Cr ▲14.0% | ₹1.5K Cr ▼1.3% | ₹1.5K Cr ▲5.7% | ₹1.4K Cr ▲3.0% | ₹1.4K Cr ▼1.6% | ₹1.4K Cr ▲0.3% | ₹1.4K Cr |
| Op. Profit | ₹513 Cr ▲17.9% | ₹435 Cr ▲38.5% | ₹314 Cr ▼14.7% | ₹368 Cr ▲5.7% | ₹348 Cr ▼3.3% | ₹360 Cr ▲21.2% | ₹297 Cr ▲12.5% | ₹264 Cr |
| OPM | 29.0% ▲11.5% | 26.0% ▲23.8% | 21.0% ▼12.5% | 24.0% ▲0.0% | 24.0% ▼7.7% | 26.0% ▲23.8% | 21.0% ▲10.5% | 19.0% |
| Net Profit | ₹367 Cr ▲40.6% | ₹261 Cr ▲41.8% | ₹184 Cr ▼14.4% | ₹215 Cr ▲15.0% | ₹187 Cr ▼8.8% | ₹205 Cr ▲25.0% | ₹164 Cr ▲13.9% | ₹144 Cr |
| EPS (₹) | 22.26 ▲40.3% | 15.87 ▲42.3% | 11.15 ▼14.8% | 13.08 ▲15.5% | 11.32 ▼8.9% | 12.42 ▲25.1% | 9.93 ▲13.7% | 8.73 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹6.4K Cr ▲14.5% | ₹5.6K Cr ▼0.9% | ₹5.7K Cr ▲56.3% | ₹3.6K Cr ▼17.6% | ₹4.4K Cr ▲27.1% | ₹3.5K Cr ▲31.5% | ₹2.6K Cr |
| Expenses | ₹4.8K Cr ▲10.4% | ₹4.3K Cr ▲0.4% | ₹4.3K Cr ▲66.6% | ₹2.6K Cr ▼10.0% | ₹2.9K Cr ▲33.7% | ₹2.2K Cr ▲28.8% | ₹1.7K Cr |
| Op. Profit | ₹1.6K Cr ▲28.4% | ₹1.3K Cr ▼4.8% | ₹1.3K Cr ▲30.0% | ₹1.0K Cr ▼32.1% | ₹1.5K Cr ▲16.0% | ₹1.3K Cr ▲36.3% | ₹955 Cr |
| OPM | 25.0% ▲8.7% | 23.0% ▼4.2% | 24.0% ▼14.3% | 28.0% ▼17.6% | 34.0% ▼10.5% | 38.0% ▲5.6% | 36.0% |
| Other Income | ₹292 Cr ▲36.4% | ₹214 Cr ▲25.9% | ₹170 Cr ▼7.6% | ₹184 Cr ▼17.9% | ₹224 Cr ▲65.9% | ₹135 Cr ▼2.9% | ₹139 Cr |
| Interest | ₹33 Cr ▼21.4% | ₹42 Cr ▲61.5% | ₹26 Cr ▲271.4% | ₹7 Cr ▲40.0% | ₹5 Cr ▲66.7% | ₹3 Cr ▼57.1% | ₹7 Cr |
| Depreciation | ₹424 Cr ▲12.2% | ₹378 Cr ▲9.6% | ₹345 Cr ▲134.7% | ₹147 Cr ▲33.6% | ₹110 Cr ▲11.1% | ₹99 Cr ▲4.2% | ₹95 Cr |
| PBT | ₹1.5K Cr ▲37.8% | ₹1.1K Cr ▼6.2% | ₹1.1K Cr ▲7.4% | ₹1.1K Cr ▼34.8% | ₹1.6K Cr ▲21.3% | ₹1.3K Cr ▲34.4% | ₹993 Cr |
| Tax % | 30.0% ▼11.8% | 34.0% ▲6.3% | 32.0% ▲23.1% | 26.0% ▲4.0% | 25.0% ▲0.0% | 25.0% ▲13.6% | 22.0% |
| Net Profit | ₹1.0K Cr ▲46.9% | ₹699 Cr ▼9.5% | ₹772 Cr ▼1.2% | ₹781 Cr ▼35.6% | ₹1.2K Cr ▲21.6% | ₹997 Cr ▲29.0% | ₹773 Cr |
| EPS (₹) | 62.35 ▲47.1% | 42.4 ▼9.6% | 46.9 ▼1.1% | 47.42 ▼35.7% | 73.75 ▲21.0% | 60.94 ▲22.2% | 49.88 |
| Div Payout | 32.0% ▼23.8% | 42.0% ▼2.3% | 43.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Liabilities | |||||||
| Equity Capital | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr |
| Reserves | ₹10.3K Cr ▲13.2% | ₹9.1K Cr ▲4.9% | ₹8.7K Cr ▲9.6% | ₹7.9K Cr ▲11.2% | ₹7.1K Cr ▲21.3% | ₹5.9K Cr ▲62.1% | ₹3.6K Cr |
| Borrowings | ₹284 Cr ▼9.6% | ₹314 Cr ▼15.6% | ₹372 Cr ▲9200.0% | ₹4 Cr ▼20.0% | ₹5 Cr ▲0.0% | ₹5 Cr ▲0.0% | ₹5 Cr |
| Other Liabilities | ₹1.9K Cr ▲9.4% | ₹1.7K Cr ▲12.7% | ₹1.5K Cr ▲86.1% | ₹814 Cr ▲21.3% | ₹671 Cr ▲14.1% | ₹588 Cr ▲35.2% | ₹435 Cr |
| Total Liabilities | ₹12.5K Cr ▲12.0% | ₹11.2K Cr ▲5.3% | ₹10.6K Cr ▲20.9% | ₹8.8K Cr ▲12.1% | ₹7.8K Cr ▲20.6% | ₹6.5K Cr ▲59.0% | ₹4.1K Cr |
| Assets | |||||||
| Fixed Assets | ₹4.5K Cr ▲8.3% | ₹4.1K Cr ▲5.1% | ₹3.9K Cr ▲151.2% | ₹1.6K Cr ▲4.6% | ₹1.5K Cr ▲57.4% | ₹954 Cr ▼1.4% | ₹968 Cr |
| CWIP | ₹342 Cr ▲126.5% | ₹151 Cr ▼36.6% | ₹238 Cr ▲34.5% | ₹177 Cr ▼7.3% | ₹191 Cr ▼43.5% | ₹338 Cr ▲79.8% | ₹188 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr ▼100.0% | ₹155 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹7.7K Cr ▲11.7% | ₹6.9K Cr ▲7.0% | ₹6.4K Cr ▼8.6% | ₹7.0K Cr ▲17.4% | ₹6.0K Cr ▲15.0% | ₹5.2K Cr ▲77.7% | ₹2.9K Cr |
| Total Assets | ₹12.5K Cr ▲12.0% | ₹11.2K Cr ▲5.3% | ₹10.6K Cr ▲20.9% | ₹8.8K Cr ▲12.1% | ₹7.8K Cr ▲20.6% | ₹6.5K Cr ▲59.0% | ₹4.1K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.0K Cr ▲12.7% | ₹915 Cr ▼8.2% | ₹997 Cr ▲173.9% | ₹364 Cr ▼54.0% | ₹791 Cr ▲30.7% | ₹605 Cr ▼13.7% | ₹701 Cr |
| Investing CF | ₹138 Cr ▼92.0% | ₹1.7K Cr ▲198.2% | ₹-1.7K Cr ▼244.4% | ₹1.2K Cr ▲221.2% | ₹-999 Cr ▲34.3% | ₹-1.5K Cr ▼99.7% | ₹-761 Cr |
| Financing CF | ₹-417 Cr ▲3.7% | ₹-433 Cr ▲45.8% | ₹-799 Cr ▼5426.7% | ₹15 Cr ▼57.1% | ₹35 Cr ▼97.2% | ₹1.2K Cr ▲17785.7% | ₹-7 Cr |
| Net Cash Flow | ₹752 Cr ▼65.8% | ₹2.2K Cr ▲241.7% | ₹-1.6K Cr ▼197.6% | ₹1.6K Cr ▲1013.8% | ₹-174 Cr ▼153.9% | ₹323 Cr ▲582.1% | ₹-67 Cr |
| Free Cash Flow | ₹538 Cr ▲3.3% | ₹521 Cr ▼13.0% | ₹599 Cr ▲324.8% | ₹141 Cr ▼47.6% | ₹269 Cr ▼28.6% | ₹377 Cr ▼28.9% | ₹530 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 107d ▲8.1% | 99d ▼1.0% | 100d ▲13.6% | 88d ▼11.1% | 99d ▲39.4% | 71d ▼14.5% | 83d |
| Inventory Days | 284d ▼3.4% | 294d ▲5.8% | 278d ▼34.0% | 421d ▲105.4% | 205d ▼34.3% | 312d ▲24.8% | 250d |
| Days Payable | 136d ▼4.9% | 143d ▲10.9% | 129d ▲1.6% | 127d ▲58.8% | 80d ▼17.5% | 97d ▲18.3% | 82d |
| Cash Conv. Cycle | 255d ▲2.0% | 250d ▲0.0% | 250d ▼34.6% | 382d ▲69.8% | 225d ▼21.3% | 286d ▲13.9% | 251d |
| Working Capital Days | 145d ▼16.2% | 173d ▲11.6% | 155d ▼36.0% | 242d ▲44.0% | 168d ▼0.6% | 169d ▲5.0% | 161d |
| ROCE | 15.0% ▲25.0% | 12.0% ▼14.3% | 14.0% ▼6.7% | 15.0% ▼40.0% | 25.0% ▼10.7% | 28.0% | — |
Source: Screener.in · Lower days = better efficiency
About Gland Pharma Limited
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Healthcare · Pharmaceuticals & Biotechnology